In 2007, Bayer took over Schering AG and formed Bayer Schering Pharma. The acquisition of Schering was the largest take-over in Bayers history. The name was changed to Bayer Pharma in 2011. Bayer Healthcare Pharmaceuticals is divided into two business units – General Medicine and Specialty Medicine. Womens healthcare is an example of a General Medicine business unit. Bayer Pharma produces the birth control pills Yaz and Yasmin. Both pills use a newer type of progesterone hormone called drospirenone in combination with estrogen. Yaz is advertised as a treatment for premenstrual dysphoric disorder and moderate acne. Other key products include the cancer drug Nexavar, the multiple sclerosis drug betaferon/betaseron and the blood-clotting drug, Kogenate. An example of a Specialty Medicine Business Unit is Diagnostic Imaging. Contrast agents from this unit helps play a crucial role in precise and early diagnosis and the selection of optimal treatment. Diagnostic imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound are used to make tissues and organs visible in their natural position inside the body along with contrast. Work is also focused on the development of tracers for positron emission tomography (PET). The PET tracer florbetaben F18 in Bayers pipeline makes it possible to recognize beta amyloid, one of the pathological hallmarks of Alzheimers disease, with high accuracy very early on and while the patient is still alive.
The following is the list of scholars from Bayer HealthCare who contributed and/or serves as editors for one or more OMICS International journals and conferences
The following is the list of articles by scholars from Bayer HealthCare that are published in OMICS International journals.
The following is the list of proceedings by scholars from Bayer HealthCare that are published in OMICS International journals and conferences.